Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:45:29.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Page footer revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:46:54.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Added: Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T21:24:13.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added in the page footer, replacing Revision: v3.3.3. This is a minor site update and does not affect the study details or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T04:44:18.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Added a dedicated Locations section with California sites; removed California Locations and the HHS Vulnerability Disclosure link, and updated the page to revision v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:39:09.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Footer shows Revision: v3.3.2 replacing v3.2.0; no study details, eligibility criteria, or results are altered. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T10:21:45.000Z thumbnail image

Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.